Novel Prostate Cancer Risk Classifier Highly Prognostic for Metastases

Video

This video highlights a clinical-genomic risk classification system that is highly prognostic for distant metastasis and more accurate than clinical risk assessments.

In this video, Daniel Eidelberg Spratt, MD, of the University of Michigan, discusses how the use of a readily available genomic classifier combined with clinicopathologic variables can generate a simple to use clinical-genomic risk classification system that is highly prognostic for distant metastasis and more accurate than clinical risk assessments.

Spratt presented results of the study (abstract 5000) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Recent Videos
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content